🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT07204665
Enrolling by invitation Observational

This Study Has Been Designed to Support the Working Hypothesis That Emergency Surgery in a Colon Obstruction Neoplasm is Better Than Stent Bridge Due to Better Oncological Outcomes, Analyzing the Importance of ERAS Programs in Emergency Colon Obstruction Surgery.

NCT07204665 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2025-07-01
Last updated
2025-10-02

Condition(s) studied

Colon Obstruction

Study summary

This study has been designed to support the working hypothesis that emergency surgery in a colon obstruction neoplasm is better than stent bridge due to better oncological outcomes. The primary objective is to analyse the importance of ERAS program implementation in emergency colon obstruction surgery

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria * All adult patients (aged \>18 years) with a diagnosis of Malignant obstruction colorectal cancer. Informed consent will be obtained from all subjects who will participate in the study voluntarily. * ASA I, II and III * No more than 5 days from symptoms onset. * Absence of proximal colon severe dilatation( no more than 8 centimeters), severe malnutrition. * No Inmunocompromised patients * Patients suffer from segmentary colectomy, with or without anastomosis with o witjhout lateral ileostomy * Patients suffer from Hartmann procedure. Exclusion criteria: * Patient refusal. * Patients under 18 years of age. * ASA IV * Stent placement * ICU stay more than 2 days * Peritonitis * Out of protocol if patient would need total parenteral nutrition(NPT) during postoperative or Clavien-Dindo more or equal than II.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hospital de Urduliz Bilbao Vizcaya

More Universidad de Zaragoza trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07204665 on ClinicalTrials.gov ↗ ← All trials in Spain